Method for predicting the clinical response of oncolytic parvovirus H1 (H-1PV) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample

A method of detecting an elevated level of a biomarker as compared with a predetermined reference level of the biomarker for determining whether a human patient suspected to suffer from cancer is a candidate for H-1PV therapy for said cancer, and treatment of said cancer thereof, comprising;

• (a) obtaining a biological sample from the patient, the biological sample comprising a tissue biopsy, blood sample, serum sample, or plasma sample;
• and
• (b) subjecting the patient's biological sample to at least one assay to measure the presence of the biomarker;
• and
• (c) detecting the elevated level of the biomarker when the measured level of the biomarker exceeds the predetermined reference level of the biomarker by at least threefold,
• whereby detecting the elevated level of the biomarker as compared with that of the predetermined reference level of the biomarker indicates that the patient will benefit from a H-1PV therapy;
• and
• (d) administering H-1PV therapy to the patient having the elevated level of the biomarker;
• wherein the biomarker comprises laminin and/or galactin;
• and
• wherein the predetermined reference level of the biomarker is determined as a value between the 25th and 75th percentile of the overall distribution of biomarker measurements from samples obtained from healthy individuals or from a population of patients within the same disease entity.